BioCatalystWatch
RGNXWorkspace / RGNX / OverviewCompany library
Price
Market cap
Next catalystExpected Q4 2026Surabgene lomparvovec — wet AMD studies · Data readoutCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

RGX-202

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

RGX-202

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

RGX-202

Upcoming / outlook

Partner / License out

Surabgene lomparvovec — wet AMD studies

VEGF

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Gene therapy

VEGF

PreINDP1P2P3FilingApproved

Approved / commercial

History / paused

PreINDP1P2P3FilingApproved

Gene therapy

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

RGNX SEC archive